ARGX - argenx NV ADR logo

argenx NV ADR

ARGX

argenx NV develops therapies for autoimmune diseases, offering products like VYVGART and VYVGART HYTRULO. Its pipeline includes treatments for various conditions, utilizing a precision-immunology platform and FcRn antagonism to target autoantibodies.

βš•οΈ Healthcare NASDAQ Listed 2017 € EUR
$1,000 invested 5 years ago β†’$3,175today

Score Overview

1 Year
Score
Net Growth100.90%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth72.04%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score8.6
Net Growth8x
Net Trend80%
Net Income Consistencyβ€”
Rev Growth14x
Rev Trend80%
Revenue Consistencyβ€”
All Time
Score
Net Growth79x
Net Trend56%
Net Income Consistency
Rev Growth163x
Rev Trend67%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where argenx NV ADR has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on all available years of fundamentals. ARGX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 958.91β€”
1 Year2025-09-30
$ 737.5630.01%
5 Years2021-09-30
$ 302.00217.52%
All Time2017-05-18
$ 23.0041x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in EUR

Year
TTM€ 7.14B€ 2.59B€ 5.18B
2025€ 4.15B€ 1.29B€ 4.44B
2024€ 2.19B€ 833M€ 3.37B
2023€ 1.22B-€ 295M€ 3.17B
2022€ 410M-€ 709M€ 2.19B
2021€ 497M-€ 407M€ 2.33B
2020€ 41M-€ 608M€ 1.99B
2019€ 78M-€ 181M€ 1.50B
2018€ 24M-€ 76M€ 645M
IPO2017€ 43M-€ 33M€ 431M
ARGX - argenx NV ADR logo

argenx NV ADR fundamental performance

Between 2020 and 2025, revenue grew from € 41M to € 4.15B and net income went from -€ 608M to € 1.29B. Revenue increased in 4 of those 5 years; net income in 4.

Across argenx NV ADR's full reported history, from 2017 to 2025, revenue grew from € 43M to € 4.15B and net income went from -€ 33M to € 1.29B. Revenue increased in 67% of the years measured; net income in 56%.

argenx NV ADR currently holds a 5-year HDB Score of 8.6 out of 10. How the HDB Score is calculated.

Membership

Explore ARGX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies